Alerjik Konjonktivit ile İlgili Güncel Bilgiler
PDF
Atıf
Paylaş
Talep
Derleme
CİLT: 51 SAYI: 1
P: 45 - 54
Ocak 2021

Alerjik Konjonktivit ile İlgili Güncel Bilgiler

Turk J Ophthalmol 2021;51(1):45-54
1. San Carlos de Madrid Hastanesi, Göz Hastalıkları Anabilim Dalı, Madrid, İspanya
2. Madrid Complutense Üniversitesi, Ramón Castroviejo Göz Hastalıkları Araştırma Enstitüsü, Madrid, İspanya
3. Clínica Rementería, Madrid, İspanya
Bilgi mevcut değil.
Bilgi mevcut değil
Alındığı Tarih: 10.02.2020
Kabul Tarihi: 03.06.2020
Yayın Tarihi: 25.02.2021
PDF
Atıf
Paylaş
Talep

ÖZET

Alerjik konjonktivit, çocukları ve yetişkinleri etkileyen, yaşam kalitesinin bozulmasına ve bazen geri dönüşü olmayan görme hasarına neden olan prevalansı giderek artan bir hastalıktır. Hastalığın çeşitli formları vardır. Bazıları mevsimsel ve perennial alerjik konjonktivit, dev papiller konjonktivit ve kontakt alerjik blefarokonjonktivit gibi alerjen kaynaklı iken, vernal keratokonjonktivit ve atopik keratokonjonktivit gibi diğerleri her zaman alerjen maruziyeti ile açıklanamamaktadır. Bu derlemede alerjik konjonktivitin klinik seyri, karakteristik özellikleri ve ayırıcı tanısını gözden geçiriyor, patofizyoloji ve tedavideki son gelişmeleri vurguluyoruz.

Anahtar Kelimeler:
Alerjik konjonktivit, alerjik keratokonjonktivit, kontakt blefarokonjonktivit, vernal keratokonjonktivit, atopik keratokonjonktivit, oküler alerji

Sonuç

Sonuç olarak, son yıllarda oküler alerji ve tedavisi hakkında önemli gelişmeler olduğunu ve artık hastalığın çoğu formunun etkili ve güvenli bir şekilde yönetilebildiğini vurgulamak isteriz. İkili ajanlar birinci basamak tedavi olarak kabul edilmektedir; semptomlar kontrol edilemediğinde, hekimler kısa süreli topikal steroidleri düşünebilirler. Bu tedavilere ek olarak oral antihistaminikler veya topikal oftalmik NSAİİ’ler kullanılabilir ve bir sonraki adım topikal kalsinörin inhibitörlerin endikasyon dışı kullanılmasıdır. İmmünoterapi, semptomların uzun süreli giderilmesini sağlayabilir ve tıbbi tedavi yetersiz ise veya iyi tolere edilemiyorsa göz önünde bulundurulmalıdır. Ancak bu alanda tedavilerin optimal dozlarının standardizasyonu gibi henüz netlik kazanmamış önemli eksikler vardır. Gelecekte özellikle immünomodülasyon ve immünoterapide farmakolojik gelişmeler olması beklenmektedir.

Hakem Değerlendirmesi: Editörler kurulu ve editörler kurulu dışında olan kişiler tarafından değerlendirilmiştir.

Yazarlık Katkıları

Konsept: J.M.B.C., Dizayn: J.M.B.C., Veri Toplama veya İşleme: B.V.V., Analiz veya Yorumlama: J.M.B.C., Literatür Arama: B.V.V., Yazan: B.V.V., J.M.B.C.
Çıkar Çatışması: Yazarlar tarafından çıkar çatışması bildirilmemiştir.
Finansal Destek: Yazarlar tarafından finansal destek almadıkları bildirilmiştir.

Kaynaklar

1
Patel N, Venkateswaran N, Wang Z, Galor A. Ocular involvement in atopic disease: a review. Curr Opin Ophthalmol. 2018;29:576-581.
2
Butrus S, Portela R. Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am. 2005;18:485-492.
3
Palmares J, Delgado L, Cidade M, Quadrado MJ, Filipe HP; Season Study Group. Allergic conjunctivitis: a national cross-sectional study of clinical characteristics and quality of life. Eur J Ophthalmol. 2010;20:257-264.
4
Fauquert JL. Diagnosing and managing allergic conjunctivitis in childhood: The allergist’s perspective. Pediatr Allergy Immunol. 2019;30:405-414.
5
Dupuis P, Prokopich CL, Hynes A, Kim H. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunol. 2020;16:5.
6
Fauquert JL, Jedrzejczak-Czechowicz M, Rondon C, Calder V, Silva D, Kvenshagen BK, Callebaut I, Allegri P, Santos N, Doan S, Perez Formigo D, Chiambaretta F, Delgado L, Leonardi A; Interest Group on Ocular Allergy (IGOA) from the European Academy of Allergy and Clinical Immunology. Conjunctival allergen provocation test : guidelines for daily practice. Allergy. 2016;72:43-54.
7
Leonardi A, Bogacka E, Fauquert JL, Kowalski ML, Groblewska A, Jedrzejczak-Czechowicz M, Doan S, Marmouz F, Demoly P, Delgado L. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy. 2012;67:1327-1337.
8
Bielory L, Schoenberg D. Emerging therapeutics for ocular surface disease. Curr Allergy Asthma Rep. 2019;28;19:16.
9
O’Brien TP. Allergic conjunctivitis: an update on diagnosis and management. Curr Opin Allergy Clin Immunol. 2013;13:543-549.
10
Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007;62(Suppl 85):17-25.
11
Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R, Halken S, Larenas-Linnemann D, Pawankar R, Pitsios C, Sheikh A, Worm M, Arasi S, Calderon MA, Cingi C, Dhami S, Fauquert JL, Hamelmann E, Hellings P, Jacobsen L, Knol EF, Lin SY, Maggina P, Mösges R, Oude Elberink JNG, Pajno GB, Pastorello EA, Penagos M, Rotiroti G, Schmidt-Weber CB, Timmermans F, Tsilochristou O, Varga EM, Wilkinson JN, Williams A, Zhang L, Agache I, Angier E, Fernandez-Rivas M, Jutel M, Lau S, van Ree R, Ryan D, Sturm GJ, Muraro A. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73:765-798.
12
Meltzer E, Farrar J, Sennett C. Findings from and online survey assessing the burden and management of seasonal allergic rhinoconjunctiviis in us patients. J Allergy Clin Immunol Pract. 2017;5:779-789.
13
Klossek JM, Annesi-Maesano I, Pribil C, Didier A. The burden associated with ocular symptoms in allergic rhinitis. Int Arch Allergy Immunol. 2012;158:411-417.
14
Foster CS. The pathophysiology of ocular allergy: current thinking. Allergy. 1995;50(21 Suppl):6-9.
15
Bonini S. Allergy and the eye. Chem Immunol Allergy. 2014;100:105-108.
16
La Rosa M, Lionetti E, Reibaldi M, Russo A, Longo A, Leonardi S, Tomarchio S, Avitabile T, Reibaldi A. Allergic conjunctivitis: a comprehensive review of the literature. Ital J Pediatr. 2013;39:18.
17
Berger WE, Granet DB, Kabat AG. Diagnosis and management of allergic conjunctivitis in pediatric patients. Allergy Asthma Proc. 2017;38:16-27.
18
Friedlander MH. Ocular Allergy. Curr Opin Allergy Clin Immunol. 2011;11:477-482.
19
Andersen HH, Yosipovitch G, Galor A. Neuropathic symptoms of the ocular surface: dryness, pain and itch. Curr Opin Allergy Clin Immunol. 2017;17:373-381.
20
Chen L, Pi L, Fang J, Chen X, Ke N, Liu Q. High incidence of dry eye in young children with allergic conjunctivitis in Southwest China. Acta Ophthalmol. 2016;94:727-730.
21
De Smedt S, Wildner G, Kestelyn P. Vernal keratoconjunctivitis: an update. Br J Ophthalmol. 2013;97:9-14.
22
Addis H, Jeng BH. Vernal Keratoconjunctivitis. Clinical Ophthalmol. 2018:12;119-123.
23
Esposito S, Fior G, Mori A, Osnaghi S, Ghiglioni D. An update on the therapeutic approach to vernal keratoconjunctivitis. Pediatr Drugs. 2016;18:347-355.
24
Bozkurt B, Artac H, Arslan N, Gokturk B, Bozkurt MK, Reisli I, Irkec M. Systemic atopy and immunoglobulin deficiency in Turkish patients with vernal keratoconjunctivitis. Ocul Immunol Inflamm. 2013;21:28-33.
25
Bozkurt B, Artac H, Ozdemir H, Ünlü A, Bozkurt MK, Irkec M. Serum Vitamin D Levels in Children with Vernal Keratoconjunctivitis. Ocul Immunol Inflamm. 2018;26:435-439.
26
Elieh Ali Komi D, Rambasek T, Bielory L. Clinical implications of mast cell involvement in allergic conjunctivitis. Allergy. 2018;73:528-539.
27
Irkeç M, Bozkurt B. Epithelial cells in ocular allergy. Curr Allergy Asthma Rep. 2003;3:352-357.
28
Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res. 2002;21:319-339.
29
Solomon A. Corneal complications of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2015;15:489-494
30
Irkeç MT, Orhan M, Erdener U. Role of tear inflammatory mediators in contact lens-associated giant papillary conjunctivitis in soft contact lens wearers. Ocul Immunol Inflamm. 1999;7:35-38.
31
Donshik PC, Ehlers WH, Ballow M. Giant papillary conjunctivitis. Immunol Allergy Clin North Am. 2008;28:83-103.
32
Iyer G, Agarwal S, Srinivasan B. Outcomes and Rationale of Excision and Mucous Membrane Grafting in Palpebral Vernal Keratoconjunctivitis. Cornea. 2018;37:172-176.
33
Pepper AN, Ledford DK. Nasal and ocular challenges. J Allergy Clin Immunol. 2018;141:1570-1577.
34
Bilkhu PS, Wolffsohn JS, Naroo SA, Robertson L, Kennedy R. Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis. Ophthalmology. 2014;121:72-78.
35
Ben-Eli H, Solomon A. Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends. Curr Opin Allergy Clin Immunol. 2018;18:411-416.
36
Bozkurt MK, Tülek B, Bozkurt B, Akyürek N, Öz M, Kiyici A. Comparison of the efficacy of prednisolone, montelukast, and omalizumab in an experimental allergic rhinitis model. Turk J Med Sci. 2014;44:439-447.
37
Holsclaw DS, Whitcher JP, Wong IG, Margolis TP. Supratarsal injection of corticosteroid in the treatment of refractory vernal keratoconjunctivitis. Am J Ophthalmol. 1996;121:243-249.
38
McSwiney TJ, Power B, Murphy CC, Brosnahan D, Power W. Safety and Efficacy of Supratarsal Triamcinolone for Treatment of Vernal Keratoconjunctivitis in Ireland. Cornea. 2019;38:955-958.
39
Bielory L, Schoenberg D. Ocular allergy: update on clinical trials. Curr Opin Allergy Clin Immunol. 2010;19:495-502.
40
De Bosscher K, Haegeman G, Elewaut D. Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol. 2010;10:497-504.
41
Hoy SM. Ciclosporin Ophthalmic Emulsion 0.1%: A Review in Severe Dry Eye Disease. Drugs. 2017;77:1909-1916.
42
Moote W, Kim H, Ellis AK. Allergen-specific immunotherapy. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):53.
43
Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database Syst Rev. 2011;7:CD007685.
44
Bielory BP, Shah SP, O’Brien TP, Perez VL, Bielory L. Emerging therapeutics for ocular surface disease. Curr Opin Allergy Clin Immunol. 2016;16:477-486.
45
van der Schaft J, Thijs JL, de Bruin-Weller MS, Balak DMW. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what’s new and what’s next? Curr Opin Allergy Clin Immunol. 2019;19:341-349.
46
Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol. 2020;104:776-779.
47
Amparo F, Dastjerdi MH, Okanobo A, Ferrari G, Smaga L, Hamrah P, Jurkunas U, Schaumberg DA, Dana R. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol. 2013;131:715-723.
48
Tauber J, Karpecki P, Latkany R, Luchs J, Martel J, Sall K, Raychaudhuri A, Smith V, Semba CP; OPUS-2 Investigators. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study. Ophthalmology. 2015;122:2423-2431.
49
Nishiwaki-Dantas MC, Dantas PE, Pezzutti S, Finzi S. Surgical resection of giant papillae and autologous conjunctival graft in patients with severe vernal keratoconjunctivitis and giant papillae. Ophthalmic Plast Reconstr Surg. 2000;16:438-442.
50
Guo P, Kheirkhah A, Zhou WW, Qin L, Shen XL. Surgical resection and amniotic membrane transplantation for treatment of refractory giant papillae in vernal keratoconjunctivitis. Cornea. 2013;32:816-820.
51
Jabbehdari S, Starnes TW, Kurji KH, Eslani M, Cortina MS, Holland EJ, Djalilian AR. Management of advanced ocular surface disease in patients with severe atopic keratoconjunctivitis. Ocul Surf. 2019;17:303-309.